AACP
ANIP icon

Advantage Alpha Capital Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Advantage Alpha Capital Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,354
Closed -$582K – 8
2025
Q3 		$582K Sell
6,354
-1,598
-20% -$130K 0.18% 103
2025
Q2 		$519K Sell
7,952
-2,247
-22% -$146K 0.14% 96
2025
Q1 		$683K Buy
10,199
+10,172
+37,674% +$608K 0.17% 94
2024
Q4 		$1.49K Sell
27
-5,745
-100% -$330K ﹤0.01% 150
2024
Q3 		$344K Buy
+5,772
New +$352K 0.08% 153

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advantage Alpha Capital Partners's ANIP Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of ANI Pharmaceuticals (ANIP) in Q4 2025, closing a stake of 6,354 shares — an estimated $582K sold.

Advantage Alpha Capital Partners first reported a position in ANIP in Q3 2024 and held it in 5 quarters. The position peaked at $683K in Q1 2025. 284 funds tracked by Wall St. Rank hold ANIP as of Q4 2025.

  • Advantage Alpha Capital Partners reported no remaining ANI Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 6,354 ANI Pharmaceuticals shares in Q4 2025, an estimated $582K.
  • Advantage Alpha Capital Partners first reported a position in ANI Pharmaceuticals in Q3 2024 and held it in 5 quarters.
  • Advantage Alpha Capital Partners's ANI Pharmaceuticals position peaked at $683K in Q1 2025.
  • 284 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.